Group 1: Company Overview - The company is primarily engaged in pharmaceutical wholesale, retail, and related services [1] - The company has a development history, main business operations, and a management team that were introduced during the investor meeting [1] Group 2: Financial Performance - In the first half of 2024, the company achieved a revenue of CNY 4.986 billion, representing a growth of 5.49% [1] - The net profit for the same period was CNY 135 million, showing a year-on-year decline of 11.84% [1] Group 3: Business Development - The company currently operates 15 DTP (Direct-to-Patient) specialty pharmacies in Heilongjiang Province, focusing on oncology and immunotherapy medications [1] - The growth in the retail segment is primarily attributed to the expansion of the DTP business [1]

证券代码：600829 证券简称：人民同泰 哈药集团人民同泰医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | --- | |-------|----------------------|----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|--------|------------| | | | | | | 编号： | 2024-002 | | | | □特定对象调研 | ...

证券代码：600829 证券简称：人民同泰 编号：临 2024-016 哈药集团人民同泰医药股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 9 月 18 日（星期三）15:00-16:30 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.ssein fo.com/） 会议召开方式：上证路演中心视频录播和网络互动 投资者可于 2024 年 9 月 9 日（星期一）-2024 年 9 月 13 日（星期五）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱：renmintongtai@hyr mtt.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 哈药集团人民同泰医药股份有限公司（以下简称"公司"）已于 2024 年 8 月 9 日披露了《2024 年半年度报告》。为进一步加强与投资者的互动交流，便于 广大投资者更全面深入了解公司 2024 年 ...

本页无正文，为《哈药集团股份有限公司关于哈药集团人民同泰医药 股份有限公司股票交易异常波动问询函的回复》之盖章页: 哈 闭股价有限 六百 『年九月九日 哈药集团股份有限公司 二、在本次股票交易异常波动期间,本公司不存在买卖贵公司股 票的情况。 关于哈药集团人民同泰医药股份有限公司股票交易异常波 动间询函的回复 特此回复。 哈药集团人民同泰医药股份有限公司: 贵公司股票于 2024 年 9 月 4 日、2024 年 9 月 5 日连续两个交易 日内日收盘价格涨幅偏离值累计超过 20%,按照《上海证券交易所交 易规则》的有关规定,属于股票交易异常波动情况。贵公司发来的《哈 药集团人民同泰医药股份有限公司关于股票交易异常波动的问询函》 已收悉。针对函件所列问题,我公司回复如下： 一、本公司不存在任何应披露而未披露的影响贵公司股价异常波 动的重大信息,包括但不限于重大资产重组、股份发行、重大交易类 事项、业务重组、股份回购、股权激励、破产重整、重大业务合作、 引进战略投资者等重大事项。 ...

证券代码：600829 证券简称：人民同泰 编号：临 2024-015 哈药集团人民同泰医药股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●哈药集团人民同泰医药股份有限公司（以下简称"公司"）股票于 2024 年 9 月 4 日、 9 月 5 日连续 2 个交易日内日收盘价格涨幅偏离值累计超过 20%，属于《上海证券交易所交 易规则》规定的股票交易异常波动情形。 ●经公司自查，并向公司控股股东哈药集团股份有限公司、间接控股股东哈药集团有限 公司核实，不存在应披露而未披露的重大事项或重要信息。 ●敬请广大投资者注意二级市场交易风险，理性投资。 （二）经向公司控股股东哈药集团股份有限公司、间接控股股东哈药集团有 限公司征询确认，本公司控股股东、间接控股股东及间接控股股东的各方股东均 不存在应披露而未披露的影响公司股价异常波动的重大信息，包括但不限于重大 资产重组、股份发行、重大交易类事项、业务重组、股份回购、股权激励、破产 重整、重大业务合作、引进战略投资者等重大事项。 一、股 ...

贵公司股票于 2024年9月4日、2024年9月5日连续两个交易 日内日收盘价格涨幅偏离值累计超过 20%。贵公司发来的《哈药集团 人民同泰医药股份有限公司关于股票交易异常波动的问询函》已收悉, 针对函件所列问题,我公司回复如下: 一、截止目前,本公司及本公司各方股东均不存在应披露而未披 露的影响贵公司股价异常波动的重大信息,包括但不限于重大资产重 组、股份发行、重大交易类事项、业务重组、股份回购、股权激励、 破产重整、重大业务合作、引进战略投资者等重大事项。 二、在本次股票交易异常波动期间,本公司不存在买卖贵公司股 票的情形。 特此回复。 哈药集团有限公司 关于哈药集团人民同泰医药股份有限公司 股票交易异常波动问询函的回复 哈药集团人民同泰医药股份有限公司： ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥4,985,528,449.27, a decrease of 5.49% compared to ¥5,275,215,855.48 in the same period last year[15]. - The net profit attributable to shareholders of the listed company was ¥135,191,800.25, down 11.84% from ¥153,342,732.01 in the previous year[15]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥123,208,662.72, a decrease of 18.59% compared to ¥151,346,738.43 in the same period last year[15]. - The net cash flow from operating activities was -¥205,189,408.56, indicating a significant decline compared to ¥265,643,607.92 in the previous year[15]. - The basic earnings per share decreased by 11.84% to 0.2331 RMB per share compared to 0.2644 RMB per share in the previous year[16]. - The gross profit margin was 9.08%, a decline of 0.29% from the previous year[31]. - The total profit for the first half of 2024 was CNY 176,912,063.92, down from CNY 204,376,065.24 in the previous year, reflecting a decline of approximately 13.4%[80]. - The total comprehensive income for the first half of 2024 was CNY 135,191,800.24, compared to CNY 153,434,441.40 in the first half of 2023, reflecting a decrease of about 11.9%[83]. Assets and Liabilities - Total assets at the end of the reporting period were ¥7,188,959,728.32, a decrease of 3.20% from ¥7,426,464,728.93 at the end of the previous year[15]. - The net assets attributable to shareholders at the end of the reporting period were ¥2,803,106,065.32, an increase of 1.88% from ¥2,751,418,223.04 at the end of the previous year[15]. - The company's cash and cash equivalents decreased to CNY 1.02 billion from CNY 1.31 billion, representing a decline of approximately 22.5%[72]. - Current liabilities totaled CNY 4.23 billion, down from CNY 4.52 billion, reflecting a decrease of about 6.4%[73]. - The total liabilities decreased to CNY 4,385,896,421.59 from CNY 4,675,089,264.47, indicating a reduction in financial leverage[74]. Revenue Segments - The wholesale segment saw a revenue decline of 7.18% year-on-year, while the retail segment grew by 3.87%[16]. - The wholesale business generated revenue of 412,452.47 million yuan, with medical distribution revenue at 297,449.19 million yuan and commercial allocation revenue at 115,003.28 million yuan[32]. - The retail business reported revenue of 79,284.89 million yuan, with 389 direct-operated stores, including 245 in Harbin[35]. Membership and Customer Base - The company expanded its membership base to 2.47 million, an increase of nearly 220,000 members compared to the same period last year[27]. - The company maintained a member sales ratio of approximately 78%[31]. Operational Efficiency - The company is focusing on enhancing service quality and operational efficiency to adapt to market changes and improve customer satisfaction[30]. - The company is actively developing a multi-platform marketing model, integrating online and offline services to enhance customer convenience[24]. - The logistics center processed 2.32 million items and served an average of 906 customers daily during the reporting period[39]. Risk Management - The company faces risks from industry policy changes, intensified market competition, information system security, and accounts receivable management, which could impact cash flow and operational stability[51]. - To mitigate risks, the company plans to enhance management capabilities, adjust operational strategies, and improve service quality to maintain competitiveness in the pharmaceutical distribution market[51]. Environmental and Social Responsibility - The company has not reported any environmental violations or received administrative penalties related to environmental protection during the reporting period[56]. - The company adheres to the principles of ecological civilization construction and actively responds to national "carbon neutrality" and "carbon peak" policies, focusing on energy conservation and emission reduction in daily operations[57]. - The company implements strict management of dining services to reduce food waste, in line with the national "Anti-Food Waste Law," effectively minimizing grain waste[58]. Shareholder Information - The company reported a total of 23,994 common shareholders as of the end of the reporting period[67]. - Harbin Pharmaceutical Group Co., Ltd. holds 74.82% of the company's shares, totaling 433,894,354 shares[67]. Accounting Policies - The financial statements are prepared based on the accrual basis of accounting, in accordance with the accounting standards issued by the Ministry of Finance[95]. - The company’s accounting policies include depreciation of fixed assets and amortization of intangible assets, tailored to its operational characteristics[96]. - The company’s fiscal year runs from January 1 to December 31, with a business cycle of 12 months[98][99]. Accounts Receivable - The company's accounts receivable balance at the end of the period is CNY 4,441,208,023.75, an increase from CNY 4,375,477,733.00 at the beginning of the period[167]. - The total accounts receivable balance is CNY 4,441,208,023.75, with a bad debt provision of CNY 207,803,390.45, resulting in a provision ratio of 4.68%[172]. - The company has a significant amount of accounts receivable from large customers, with CNY 1,717,348,824.13 being less than one year old, and a provision of CNY 110,708,919.30[171]. Inventory Management - The total inventory at the end of the period is CNY 1,076,549,393.58, with a provision for inventory depreciation of CNY 1,822,224.86[188]. - The raw materials account for CNY 1,169,278.58, while the work-in-progress is valued at CNY 2,816,624.86[188]. Investment and Capital Management - The company reported a significant increase in expected credit losses, with provisions calculated based on the weighted average of credit losses for financial instruments[122]. - The company capitalizes borrowing costs directly attributable to the acquisition or production of qualifying assets, ceasing capitalization once the asset is ready for use[140].

证券代码：600829 证券简称：人民同泰 公告编号：2024-014 哈药集团人民同泰医药股份有限公司 2023 年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.144 元（含税） 相关日期 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本 579,888,597 股为基数，每股派发 现金红利 0.144 元（含税），共计派发现金红利 83,503,957.97 元。 三、 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2024/7/24 | － | 2024/7/25 | 2024/7/25 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日 ...

哈药集团人民同泰医药股份有限公司 2023 年年度股东大会会议资料 哈药集团人民同泰医药股份有限公司 2023年年度股东大会 会议资料 （股票代码：600829） 会议日期：二〇二四年六月六日 - 1 - 四、对有关询问进行回答；（若有） 哈药集团人民同泰医药股份有限公司 2023 年年度股东大会会议资料 哈药集团人民同泰医药股份有限公司 2023年年度股东大会议程 会议时间：2024年6月6日 14:00 会议地点：哈尔滨市道里区哈药路418号公司七楼会议室 会议主持人：董事长 朱卫东 会议议程：一、主持人宣布会议开始，宣读会议议程及须知； 二、会议审议事项： | 序号 | 议案名称 | | --- | --- | | 1 | 2023 年度董事会工作报告 | | 2 | 2023 年度监事会工作报告 | | 3 | 2023 年年度报告及摘要 | | 4 | 2023 年度财务决算报告 | | 5 | 2024 年度财务预算报告 | | 6 | 2023 年度利润分配预案 | | 7 | 关于公司 2024 年度日常关联交易预计的议案 | | 8 | 关于授权公司董事会申请综合授信额度及银行贷款的议案 | ...

哈药集团人民同泰医药股份有限公司 股权投资管理制度 第一章 总则 第一条 为加强哈药集团人民同泰医药股份有限公司（以下简称 "股份公司"或"公司"）股权类投资项目管理，规范公司的股权投 资行为，防范投资风险，保证投资安全，实现公司资本运作战略，结 合公司的实际情况，制定本管理制度。 第二条 本管理制度适用于股份公司及其所属各企业（包括全资、 控股以及实际控制企业）（以下简称"各企业"）。 第四条 公司各项股权投资纳入规范化、制度化管理，即每项投 资从立项、可行性研究、市场调研、重大风险识别到最终投资项目的 确立和实行等，均贯彻到人、责任到人，建立相应的项目责任制，严 格选派股权投资项目实际负责人，并明确其权力、责任和义务，实行 跟踪指导、监督和考核。 第五条 股份公司及各企业股权投资需遵守法律、法规、各项规 章及《公司章程》等规定，并遵循战略引领、依法合规、能力匹配、 合理回报的基本原则。 第六条 公司股东大会及董事会是公司股权投资的决策机构，按 照《公司章程》约定履行相应决策程序。股份公司所属各企业股权投 资行为须按照其《公司章程》要求进行股权投资决策，履行章程约定 的决策程序，未经股份公司董事会批准不得开 ...